Bristol-Myers Squibb

In December 2016, Bristol-Myers Squibb was granted exclusive worldwide rights to NG-348. PsiOxus will lead pre-IND activities and Bristol-Myers Squibb is responsible for all clinical development and commercialization. View the partnership announcement.

In June 2016, Bristol-Myers Squibb and PsiOxus partnered on a clinical collaboration to evaluate Enadenotucirev in combination with nivolumab to investigate their use in several tumor types (the SPICE study). View the collaboration announcement.

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image